Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Agenda 2015 – Bonus Question

After asking industry leaders about all the issues we thought would matter most in 2015, we asked them what questions they thought we had missed. Here is what they told us. • What are some of the non-traditional approaches to communicating with HCPs that are being adopted? We are starting to see a number of […]

Read More »

Prize programs lift adherence by half

  HealthPrize Technologies, a medication adherence and digital patient engagement company, has announced positive results from a number of pharmaceutical company sponsored patient support programs conducted across a variety of chronic conditions, including diabetes, hypertension, acne, and asthma/COPD. HealthPrize’s online and mobile platform uses gaming dynamics, behavioral economics, rewards and education to motivate patients to […]

Read More »

Changes at Endo highlight People On The Move

The executive leadership and senior management team switches are expected to aid growth after the Auxilium acquisition.   As Endo International plc prepares to acquire Aux-ilium, the company has announced changes to its executive leadership and senior management team. According to executives, the changes are designed to support Endo’s continued evolution into a leading global […]

Read More »

How pharma agencies can become patient agencies (in 5 easy steps)

By Jeff Greene If you’re a successful pharmaceutical marketing agency in 2015, you’re faced with a conundrum: • It’s getting harder for your clients to promote their products to physicians • It’s getting easier for your clients to promote their products to patients As your account team knows painfully well, pharma companies aren’t buying nearly […]

Read More »

Interactive and Digital Marketing Facts and Figures 0215

• According to a survey by TechnologyAdvice Research (technologyadvice.com), 60.8 percent of patients say digital services play an important role when choosing a physician. Less than one-third of patients surveyed say their physician offers digital services. The top three services patients would most prefer their physician to provide were the ability to view test results […]

Read More »

Sales and Marketing Facts and Figures 0215

The global EPO market is expected to reach $11.9 billion by 2020, with promising CAGR of 9.7 percentfrom 2014 to 2020, according to a report by Allied Market Research (alliedmarketresearch.com). Darbepoetin alfa is fastest growing drug class at a CAGR of 12.9 percent during the forecast period, owing to its high potency and minimal side […]

Read More »

Soligenix Completes Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn’s Disease

Princeton, NJ – June 28, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the […]

Read More »

Genentech’s Leukemia Drug Gets Priority Review

FDA Grants Genentech’s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Announcement Follows FDA Breakthrough Therapy Designation for GA101 in CLL FDA Decision on the GA101 Biologics License Application (BLA) Is Expected by the End of 2013. South San Francisco, Calif. — July 2, 2013 — Genentech, a member of the Roche […]

Read More »

Patients Show No Signs of HIV after Bone Marrow Transplant

HIV Positive Men Show No Signs of HIV after Bone Marrow Transplant and Discontinuation of Anti-Retroviral Therapy Boston, MA – Two Brigham and Women’s Hospital patients with longstanding HIV infections who underwent bone marrow transplants have stopped anti-retroviral therapy and have no detectable HIV in their blood cells.  One patient stopped anti-retroviral therapy 15 weeks […]

Read More »

FDA OKs Novartis’ Exelon Patch for Severe Alzheimer’s

Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer’s disease Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose Exelon Patch first and only transdermal therapy approved to treat […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation